Becton, Dickinson and Company (NYSE:BDX) Shares Acquired by Trust Co. of Vermont

Trust Co. of Vermont increased its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 0.7% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 69,879 shares of the medical instruments supplier’s stock after purchasing an additional 455 shares during the quarter. Trust Co. of Vermont’s holdings in Becton, Dickinson and Company were worth $16,848,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of BDX. Sound Income Strategies LLC lifted its holdings in shares of Becton, Dickinson and Company by 35.8% during the third quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock worth $40,000 after purchasing an additional 44 shares during the period. Opal Wealth Advisors LLC acquired a new stake in shares of Becton, Dickinson and Company during the second quarter worth $45,000. Abound Wealth Management lifted its holdings in shares of Becton, Dickinson and Company by 96.0% during the second quarter. Abound Wealth Management now owns 196 shares of the medical instruments supplier’s stock worth $46,000 after purchasing an additional 96 shares during the period. Chilton Capital Management LLC lifted its holdings in shares of Becton, Dickinson and Company by 1,233.3% during the second quarter. Chilton Capital Management LLC now owns 200 shares of the medical instruments supplier’s stock worth $47,000 after purchasing an additional 185 shares during the period. Finally, Tributary Capital Management LLC acquired a new stake in shares of Becton, Dickinson and Company during the first quarter worth $49,000. 86.97% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms have commented on BDX. Stifel Nicolaus raised their target price on Becton, Dickinson and Company from $270.00 to $280.00 and gave the company a “buy” rating in a report on Friday, July 26th. Citigroup raised Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and raised their target price for the company from $255.00 to $275.00 in a report on Tuesday, October 1st. Raymond James reduced their target price on Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating for the company in a report on Friday, August 2nd. StockNews.com raised Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Thursday, August 8th. Finally, Evercore ISI raised their target price on Becton, Dickinson and Company from $286.00 to $290.00 and gave the company an “outperform” rating in a report on Tuesday, October 1st. Nine analysts have rated the stock with a buy rating, According to data from MarketBeat, Becton, Dickinson and Company has a consensus rating of “Buy” and a consensus price target of $282.63.

Becton, Dickinson and Company Trading Up 0.0 %

Shares of BDX stock opened at $240.32 on Friday. Becton, Dickinson and Company has a fifty-two week low of $218.75 and a fifty-two week high of $262.23. The stock has a market cap of $69.45 billion, a P/E ratio of 52.93, a P/E/G ratio of 1.79 and a beta of 0.42. The business has a fifty day simple moving average of $236.86 and a 200-day simple moving average of $235.28. The company has a quick ratio of 1.36, a current ratio of 1.85 and a debt-to-equity ratio of 0.70.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings results on Thursday, August 1st. The medical instruments supplier reported $3.50 earnings per share for the quarter, beating analysts’ consensus estimates of $3.31 by $0.19. Becton, Dickinson and Company had a return on equity of 14.49% and a net margin of 7.13%. The business had revenue of $4.99 billion during the quarter, compared to analysts’ expectations of $5.08 billion. During the same quarter last year, the business posted $2.96 earnings per share. The business’s revenue for the quarter was up 2.3% on a year-over-year basis. On average, analysts forecast that Becton, Dickinson and Company will post 13.11 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, September 30th. Investors of record on Monday, September 9th were given a dividend of $0.95 per share. This represents a $3.80 dividend on an annualized basis and a yield of 1.58%. The ex-dividend date was Monday, September 9th. Becton, Dickinson and Company’s dividend payout ratio is presently 83.70%.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.